Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER vs HEMICLOR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium is the principal intracellular cation and is essential for maintaining cellular membrane potential, nerve impulse transmission, and muscle contraction. Dextrose provides calories and may prevent ketosis.
Hemichlor (HEMICLOR) is a brand name for a combination product containing chlorpheniramine and pseudoephedrine. Chlorpheniramine is a first-generation antihistamine that antagonizes histamine at H1 receptor sites, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
Treatment of hypokalemia,Prevention of hypokalemia,Replacement of potassium losses,Provision of fluid and caloric needs when potassium supplementation is required
Relief of symptoms associated with seasonal and perennial allergic rhinitis, including nasal congestion, sneezing, rhinorrhea, and pruritus,Off-label: Adjunctive treatment for acute sinusitis and common cold symptoms
Intravenous; typical adult dose is 10-20 m Eq/hour, not exceeding 40 m Eq/hour or 150 m Eq/day, with continuous cardiac monitoring and serum potassium monitoring.
50-100 mg intravenously every 6 hours or 100 mg orally every 12 hours.
The elimination half-life of potassium is not applicable in the traditional sense because potassium is an endogenous ion under tight homeostatic control. After intravenous infusion of a potassium load, the plasma concentration declines with a distribution phase of about 1-2 hours, followed by a slower elimination phase reflecting cellular uptake and renal excretion, with a terminal half-life of approximately 6-8 hours in patients with normal renal function.
Terminal elimination half-life 18–24 hours in normal renal function; prolonged to 36–48 hours in moderate renal impairment (Cr Cl 30–50 m L/min); adjust dosing interval in renal disease.
Potassium is not metabolized; it is excreted primarily by the kidneys. Dextrose undergoes glycolysis and oxidation to carbon dioxide and water.
Chlorpheniramine is extensively metabolized in the liver via CYP450 enzymes, primarily CYP2D6, and excreted renally as metabolites. Pseudoephedrine is partially metabolized in the liver by N-demethylation and excreted largely unchanged in urine; its metabolism is not significantly enzyme-dependent.
Renal: >90% of potassium intake is excreted by the kidneys, primarily via distal tubular secretion; fecal: <10%; minor sweat losses. In this formulation (KCl 0.22% in D5W), the potassium content is 2 m Eq per 100 m L (approximately 20 m Eq/L).
Primarily renal (85–90% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal < 5%.
Negligible (<5%). Potassium is not significantly bound to plasma proteins; it exists as free ion in serum.
70–80% (primarily to albumin).
Approximately 0.5-0.6 L/kg (total body water); reflects distribution throughout extracellular and intracellular spaces. Potassium is predominantly intracellular (98% of total body potassium is in cells); Vd for administered potassium is large due to cellular uptake.
0.3–0.5 L/kg (indicates moderate tissue distribution).
Intravenous: 100% (complete bioavailability). Oral: about 90% absorbed; however, this formulation is for IV administration only.
Oral: 40–60% (due to first-pass metabolism; food may reduce absorption).
GFR > 50 m L/min: no adjustment; GFR 10-50 m L/min: reduce total daily dose by 25-50%; GFR < 10 m L/min: reduce dose by 50-75% and monitor potassium closely. Avoid if anuria.
GFR 30-50 m L/min: 50 mg IV every 12h or 50 mg PO every 24h; GFR 10-29 m L/min: 50 mg IV every 24h or 25 mg PO every 24h; GFR <10 m L/min: 25 mg IV every 48h or avoid use.
No specific adjustment based on Child-Pugh score; however, monitor potassium levels and renal function closely due to potential hepatorenal syndrome.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Intravenous; 0.2-0.5 m Eq/kg/hour, not exceeding 1 m Eq/kg/hour or 40 m Eq/m²/hour; adjust based on serum potassium and clinical status.
5-10 mg/kg IV every 6h, max 100 mg/dose.
Cautious dosing: initial dose at lower end of adult range (10 m Eq/hour) with close monitoring of renal function and serum potassium due to decreased renal reserve and higher risk of hyperkalemia.
Start at lower end of dosing range (50 mg IV every 12h or 50 mg PO every 24h) due to reduced renal function and increased sensitivity.
Potassium chloride injection concentrate must be diluted before use to avoid fatal hyperkalemia.
No FDA black box warning is present for HEMICLOR.
Hyperkalemia risk; monitor serum potassium levels,Cardiotoxicity; ECG monitoring recommended,Risk of extravasation; do not administer intramuscularly,Use with caution in renal impairment, adrenal insufficiency, or conditions predisposing to hyperkalemia,Do not administer if solution is discolored or contains particulate matter
Cardiovascular effects: Use with caution in patients with hypertension, ischemic heart disease, or arrhythmias,CNS depression: Chlorpheniramine may cause sedation; avoid concurrent use with alcohol or other CNS depressants,Monoamine oxidase inhibitor (MAOI) interaction: Concomitant use with MAOIs or within 14 days of discontinuation can precipitate hypertensive crisis,Urinary retention: Use cautiously in patients with prostatic hypertrophy or bladder neck obstruction,Photosensitivity: Chlorpheniramine may increase risk of photosensitivity reactions
Hyperkalemia,Severe renal failure with oliguria or anuria,Adrenal insufficiency,Concomitant use of potassium-sparing diuretics,Crush syndrome,Severe hemolytic reactions
Hypersensitivity to chlorpheniramine, pseudoephedrine, or any component,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI therapy,Severe hypertension or severe coronary artery disease,Narrow-angle glaucoma,Urinary retention,Breastfeeding (relative contraindication due to pseudoephedrine excretion)
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, tomatoes, potatoes, spinach, salt substitutes) while receiving this IV solution to prevent hyperkalemia.
Avoid alcohol and grapefruit juice. Take with food to reduce gastrointestinal upset. Limit caffeine intake as it may worsen anxiety or gastrointestinal symptoms.
Potassium chloride and dextrose are not known to be teratogenic. No fetal risks have been identified in any trimester. Dextrose is a physiological nutrient. Overdose or rapid infusion may cause maternal electrolyte imbalance potentially affecting fetus.
Hemichlor (hydrochlorothiazide) is contraindicated in pregnancy due to risk of fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances. First trimester: associated with neural tube defects in animal studies and possible oligohydramnios. Second/third trimester: risk of fetal bradycardia, hyponatremia, hypokalemia, and decreased placental perfusion.
Potassium and dextrose are normal constituents of breast milk. No adverse effects anticipated. Use considered safe during breastfeeding. M/P ratio not established.
Hydrochlorothiazide is excreted in breast milk in low concentrations. M/P ratio approximately 0.04-0.06. No adverse effects reported in infants, but may suppress lactation at high doses. Use with caution, monitor infant for electrolyte disturbances.
No dose adjustment required. Use standard adult dosing, adjusted for maternal weight and clinical status. Monitor for fluid overload and electrolyte disturbances.
Pregnancy increases volume of distribution and renal clearance of hydrochlorothiazide, potentially reducing peak serum concentration. However, due to fetal risks, thiazide diuretics are generally avoided in pregnancy. If essential, use lowest effective dose and monitor maternal/fetal status closely. No specific dose adjustment studies exist.
This solution provides 22 m Eq/L of potassium chloride and 5% dextrose. Use with caution in patients with renal impairment, cardiac disease, or hyperkalemia. Monitor serum potassium levels closely; rate of infusion should not exceed 10 m Eq/hour typically. Avoid in patients with oliguria or anuria. Do not administer undiluted; container is for intravenous use only.
HEMICLOR contains clidinium bromide (quaternary ammonium anticholinergic) and chlordiazepoxide (benzodiazepine). Monitor for anticholinergic side effects (dry mouth, blurred vision, urinary retention, constipation). Avoid use in patients with narrow-angle glaucoma, obstructive uropathy, or myasthenia gravis. Chlordiazepoxide may cause dependence; limit duration to 4-8 weeks. Use with caution in elderly due to increased sensitivity to anticholinergic effects and risk of falls.
This medication is given through a vein to provide potassium and sugar.,Tell your healthcare provider if you have kidney problems, heart disease, or are taking any other medications.,Report any symptoms of high potassium such as muscle weakness, irregular heartbeat, or tingling sensations.,You may experience pain or irritation at the IV site; inform your nurse if this occurs.,Do not stop or change the infusion rate on your own.
Take exactly as prescribed; do not increase dose or stop abruptly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and other CNS depressants.,Report any signs of urinary retention, severe constipation, or blurred vision.,Do not share with others; risk of dependence.,Store at room temperature away from moisture and heat.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER vs HEMICLOR, answered by our medical review team.
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER is a Electrolyte Supplement that works by Potassium is the principal intracellular cation and is essential for maintaining cellular membrane potential, nerve impulse transmission, and muscle contraction. Dextrose provides calories and may prevent ketosis.. HEMICLOR is a Electrolyte Supplement that works by Hemichlor (HEMICLOR) is a brand name for a combination product containing chlorpheniramine and pseudoephedrine. Chlorpheniramine is a first-generation antihistamine that antagonizes histamine at H1 receptor sites, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER and HEMICLOR depend on the specific clinical indication. These are both Electrolyte Supplement agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous; typical adult dose is 10-20 m Eq/hour, not exceeding 40 m Eq/hour or 150 m Eq/day, with continuous cardiac monitoring and serum potassium monitoring.. The standard adult dose of HEMICLOR is: 50-100 mg intravenously every 6 hours or 100 mg orally every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER and HEMICLOR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Potassium chloride and dextrose are not known to be teratogenic. No fetal risks have been identified in any trimester. Dextrose is a physiological nutrient. Overdose or rapid infus. HEMICLOR is classified as Category C. Hemichlor (hydrochlorothiazide) is contraindicated in pregnancy due to risk of fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances. First trimester: associated . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.